Tag:
Mylan
Latest Headlines
Latest Headlines
Incentives entice Mylan to expand in Ireland
The company says it will add 500 jobs by 2016 to manufacturing and R&D for its respiratory, injectables and oral solids operations.
Mylan pledges 500 new jobs in Irish expansion
The generics company plans to spend €76 million a year for the next 5 years on building up its R&D and manufacturing facilities at two Irish sites.
With Provigil exclusivity, Teva may hike its forecast
Teva can reap sales of branded Provigil, and it can profit from the generic version.
AstraZeneca's Seroquel XR patent upheld in U.S.
AstraZeneca finally won a ruling in its attempt to protect its blockbuster Seroquel franchise from the generics onslaught.
Mylan bows out of Rottapharm bidding
The Rovati family isn't making it easy for anyone interested in bidding on Rottapharm . According to a report in Reuters , Mylan ( $MYL ) has walked away from the bargaining table after negotiators failed to overcome the family's demand that it remain in control of the company, without showing any flexibility on the price. And something had to give.
Mylan aims first Lexapro copy at Forest Labs
Good news for Mylan ( $MYL ), not so good for Forest Laboratories ( $FRX ).
Leukemia drug shortage averted for now, FDA says
Disaster averted, say federal health officials. HHS Secretary Kathleen Sebelius told Congress yesterday that new supplies of the critically scarce drug methotrexate would be released in the coming
Mylan concocts ready-to-use epilepsy drug variation
Global generic drug manufacturer Mylan ( $MYL ) has begun selling a version of the anti-epilepsy drug Levetiracetam for intravenous use in a variation intended to be safer and easy to use. Doses are
Novartis plant's quality control understaffed, inadequately trained, FDA says
Novartis ( $NVS ) temporarily pulled the curtains on its Lincoln, NE, consumer drug plant in late December. What's been going on behind those windows? Pharmalot reports that, after a recent visit, FDA
Actavis, Mylan continue defense in Digitek API suits
The family of a heart patient who died while taking atrial-fibrillation drug Digitek is appealing a West Virginia judge's ruling exonerating manufacturer Actavis and distributor Mylan ( $MYL ). Quality
